GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maravai LifeSciences Holdings Inc (NAS:MRVI) » Definitions » Gross Profit

MRVI (Maravai LifeSciences Holdings) Gross Profit : $108.3 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Maravai LifeSciences Holdings Gross Profit?

Maravai LifeSciences Holdings's gross profit for the three months ended in Dec. 2024 was $19.0 Mil. Maravai LifeSciences Holdings's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $108.3 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Maravai LifeSciences Holdings's gross profit for the three months ended in Dec. 2024 was $19.0 Mil. Maravai LifeSciences Holdings's Revenue for the three months ended in Dec. 2024 was $56.4 Mil. Therefore, Maravai LifeSciences Holdings's Gross Margin % for the quarter that ended in Dec. 2024 was 33.62%.

Maravai LifeSciences Holdings had a gross margin of 33.62% for the quarter that ended in Dec. 2024 => Competition eroding margins

During the past 7 years, the highest Gross Margin % of Maravai LifeSciences Holdings was 82.41%. The lowest was 41.79%. And the median was 53.30%.

Warning Sign:

Maravai LifeSciences Holdings Inc gross margin has been in long-term decline. The average rate of decline per year is -6.7%.


Maravai LifeSciences Holdings Gross Profit Historical Data

The historical data trend for Maravai LifeSciences Holdings's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maravai LifeSciences Holdings Gross Profit Chart

Maravai LifeSciences Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
Get a 7-Day Free Trial 204.45 658.68 714.04 140.20 108.31

Maravai LifeSciences Holdings Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.03 25.84 35.13 28.37 18.96

Competitive Comparison of Maravai LifeSciences Holdings's Gross Profit

For the Biotechnology subindustry, Maravai LifeSciences Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maravai LifeSciences Holdings's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's Gross Profit distribution charts can be found below:

* The bar in red indicates where Maravai LifeSciences Holdings's Gross Profit falls into.


;
;

Maravai LifeSciences Holdings Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Maravai LifeSciences Holdings's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=259.185 - 150.876
=108.3

Maravai LifeSciences Holdings's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=56.406 - 37.444
=19.0

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $108.3 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Maravai LifeSciences Holdings's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=19.0 / 56.406
=33.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Maravai LifeSciences Holdings  (NAS:MRVI) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Maravai LifeSciences Holdings had a gross margin of 33.62% for the quarter that ended in Dec. 2024 => Competition eroding margins


Maravai LifeSciences Holdings Gross Profit Related Terms

Thank you for viewing the detailed overview of Maravai LifeSciences Holdings's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Maravai LifeSciences Holdings Business Description

Traded in Other Exchanges
Address
10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Executives
Kurt Oreshack officer: General Counsel 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
John A Deford director C R BARD INC, 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Carl Hull director, officer: Chief Executive Officer 300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Gtcr Investment Xi Llc director, 10 percent owner 300 NORTH LASALLE STREET, SUITE 5600, CHICAGO IL 60654
Rebecca Buzzeo officer: See Remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Andrew Burch officer: See Remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Martin William E. Iii officer: See remarks C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Peter Michael Leddy officer: See Remarks 1620 FARADAY AVE, CARLSBAD CA 92008
Gregory T Lucier director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Murali Prahalad director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Lisa Sellers officer: See Remarks 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Susannah Gray director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Robert B Hance director 300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Jessica Hopfield director C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Benjamin James Daverman director 300 N. LASALLE SUITE 5600, CHICAGO IL 60654

Maravai LifeSciences Holdings Headlines

From GuruFocus